Skip to content
Screener

Kiniksa Pharmaceuticals International, plc KNSA Q2 2026 earnings

Reported July 28, 2026 · Before market open

Revenue$243.6MBeat by $17.1M
EPS$0.30Beat by $0.00
Revenue estimate$226.5M
EPS estimate$0.30
“In our clinical portfolio, KPL-387 Phase 2 data supported initiation of the pivotal Phase 3 trial, PASTORALE, which is now enrolling and dosing patients. We are excited to advance KPL-387 with its target product profile of once-monthly subcutaneous dosing in a liquid formulation. We expect to bring this potential additional treatment option to patients in the 2028/2029 timeframe. Additionally, we continue to develop KPL-1161 with a target profile of once-quarterly dosing and are on track to initiate a Phase 1 trial by the end of this year.”
Sanj K. Patel

Next report

Oct 27, 2026 (in 3 months)
Revenue estimate$256.7M
EPS estimate$0.36

Financials

Q2 2026

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation & ratios

Valuation

as of 08/04/26
See full
Market cap$5.73B+135%
Enterprise value$5.56B+146%
P/E71×-439×
P/S6.8×+2.2×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0×0.0×
Current ratio3.9×+0.3×

Segments

By segment

See full
Pharmaceutical$243.6M+55.4%

By product

See full
Collaboration-—

FAQ

When did Kiniksa Pharmaceuticals International, plc report Q2 2026 earnings?
Kiniksa Pharmaceuticals International, plc (KNSA) reported Q2 2026 earnings on July 28, 2026 before market open.
What were Kiniksa Pharmaceuticals International, plc's Q2 2026 revenue and EPS?
Kiniksa Pharmaceuticals International, plc reported revenue of $243.6M and eps of $0.30 for Q2 2026.
Did Kiniksa Pharmaceuticals International, plc beat estimates in Q2 2026?
Revenue beat the consensus estimate of $226.5M by $17.1M. EPS beat the consensus estimate of $0.30 by $0.00.
How did Kiniksa Pharmaceuticals International, plc's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 55.4% from $156.8M a year earlier and eps grew 30.4% from $0.23.
Where can I find Kiniksa Pharmaceuticals International, plc's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001730430-26-000031) and the 10-Q periodic report (0001104659-26-087545) directly on SEC EDGAR. The filing index links above go to sec.gov.